Charalambous Marios, Brodbelt David, Volk Holger A
Department of Clinical Science and Services, Royal Veterinary College, Hawkshead Lane, Hatfield AL9 7TA, Herts, UK.
BMC Vet Res. 2014 Oct 22;10:257. doi: 10.1186/s12917-014-0257-9.
Various antiepileptic drugs (AEDs) are used for the management of canine idiopathic epilepsy (IE). Information on their clinical efficacy remains limited. A systematic review was designed to evaluate existing evidence for the effectiveness of AEDs for presumptive canine IE. Electronic searches of PubMed and CAB Direct were carried out without date or language restrictions. Conference proceedings were also searched. Peer-reviewed full-length studies describing objectively the efficacy of AEDs in dogs with IE were included. Studies were allocated in two groups, i.e. blinded randomized clinical trials (bRCTs), non-blinded randomized clinical trials (nbRCTs) and non-randomized clinical trials (NRCTs) (group A) and uncontrolled clinical trials (UCTs) and case series (group B). Individual studies were evaluated based on the quality of evidence (study design, study group sizes, subject enrolment quality and overall risk of bias) and the outcome measures reported (in particular the proportion of dogs with ≥ 50% reduction in seizure frequency).
Twenty-six studies, including two conference proceedings, reporting clinical outcomes of AEDs used for management of IE were identified. Heterogeneity of study designs and outcome measures made meta-analysis inappropriate. Only four bRCTs were identified in group A and were considered to offer higher quality of evidence among the studies. A good level of evidence supported the efficacy of oral phenobarbital and imepitoin and fair level of evidence supported the efficacy of oral potassium bromide and levetiracetam. For the remaining AEDs, favorable results were reported regarding their efficacy, but there was insufficient evidence to support their use due to lack of bRCTs.
Oral phenobarbital and imepitoin in particular, as well as potassium bromide and levetiracetam are likely to be effective for the treatment of IE. However, variations in baseline characteristics of the dogs involved, significant differences between study designs and several potential sources of bias preclude definitive recommendations. There is a need for greater numbers of adequately sized bRCTs evaluating the efficacy of AEDs for IE.
多种抗癫痫药物(AEDs)用于治疗犬特发性癫痫(IE)。关于其临床疗效的信息仍然有限。本系统评价旨在评估AEDs治疗疑似犬IE有效性的现有证据。对PubMed和CAB Direct进行了无日期或语言限制的电子检索。还检索了会议论文集。纳入了客观描述AEDs对IE犬疗效的同行评审全文研究。研究分为两组,即双盲随机临床试验(bRCTs)、非双盲随机临床试验(nbRCTs)和非随机临床试验(NRCTs)(A组)以及非对照临床试验(UCTs)和病例系列(B组)。根据证据质量(研究设计、研究组规模、受试者纳入质量和总体偏倚风险)和报告的结局指标(特别是癫痫发作频率降低≥50%的犬的比例)对个体研究进行评估。
共识别出26项研究,包括两篇会议论文集,报告了用于治疗IE的AEDs的临床结局。研究设计和结局指标的异质性使得荟萃分析不合适。A组仅识别出4项bRCTs,被认为在这些研究中提供了更高质量的证据。充分的证据水平支持口服苯巴比妥和咪吡托因的疗效,中等水平的证据支持口服溴化钾和左乙拉西坦的疗效。对于其余的AEDs,报告了其疗效的有利结果,但由于缺乏bRCTs,没有足够的证据支持其使用。
特别是口服苯巴比妥和咪吡托因,以及溴化钾和左乙拉西坦可能对IE治疗有效。然而,所涉及犬的基线特征存在差异、研究设计之间存在显著差异以及几个潜在的偏倚来源使得无法给出明确的建议。需要更多规模适当的bRCTs来评估AEDs对IE的疗效。